Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Page 1
Thirty years of surgical management of pediatric pulmonary hypertension: Mid-term outcomes following reverse Potts shunt and transplantation.
Valdeolmillos E, Le Pavec J, Audié M, Savale L, Jais X, Montani D, Sitbon O, Feuillet S, Mercier O, Petit J, Humbert M, Fadel E, Belli E, Hascoët S. Valdeolmillos E, et al. Among authors: montani d. J Thorac Cardiovasc Surg. 2023 Dec 3:S0022-5223(23)01121-2. doi: 10.1016/j.jtcvs.2023.11.045. Online ahead of print. J Thorac Cardiovasc Surg. 2023. PMID: 38052251
METHODS: This single-center retrospective cohort study included 61 consecutive pediatric patients with PAH managed by RPS (2004-2020) or transplantation (1988-2020). Their mid-term outcomes were assessed. RESULTS: Compared with the 20 patients managed by RPS, the 41 transp …
METHODS: This single-center retrospective cohort study included 61 consecutive pediatric patients with PAH managed by RPS (2004-2020) or tra …
Proteomic biomarkers for survival in systemic sclerosis-associated pulmonary hypertension.
Mismetti V, Delavenne X, Montani D, Bezzeghoud S, Delezay O, Hodin S, Launay D, Marchand-Adam S, Nunes H, Ollier E, Reynaud-Gaubert M, Pastre J, Traclet J, Quetant S, Zeghmar S, Bertoletti L, Cottin V. Mismetti V, et al. Among authors: montani d. Respir Res. 2023 Nov 7;24(1):273. doi: 10.1186/s12931-023-02578-0. Respir Res. 2023. PMID: 37936223 Free PMC article.
An untargeted proteomic analysis using mass spectrometry was performed to identify plasma protein changes associated with long-term overall survival in patients with SSc-PH-ILD. RESULTS: Thirty two patients were included in the analysis, of whom 13 died during follow-up (m …
An untargeted proteomic analysis using mass spectrometry was performed to identify plasma protein changes associated with long-term o …
Pulmonary hypertension associated with lung disease: new insights into pathomechanisms, diagnosis, and management.
Olsson KM, Corte TJ, Kamp JC, Montani D, Nathan SD, Neubert L, Price LC, Kiely DG. Olsson KM, et al. Among authors: montani d. Lancet Respir Med. 2023 Sep;11(9):820-835. doi: 10.1016/S2213-2600(23)00259-X. Epub 2023 Aug 14. Lancet Respir Med. 2023. PMID: 37591300 Review.
The pulmonary vasculopathy is distinct from that of other forms of pulmonary hypertension, with vascular ablation due to loss of small pulmonary vessels being a key feature. Long-term tobacco exposure might contribute to this type of pulmonary vascular remodelling. ...
The pulmonary vasculopathy is distinct from that of other forms of pulmonary hypertension, with vascular ablation due to loss of small pulmo …
Radiological pulmonary sequelae after COVID-19 and correlation with clinical and functional pulmonary evaluation: results of a prospective cohort.
Soliman S, Soliman H, Crézé M, Brillet PY, Montani D, Savale L, Jais X, Bulifon S, Jutant EM, Rius E, Devilder M, Beurnier A, Colle R, Gasnier M, Pham T, Morin L, Noel N, Lecoq AL, Becquemont L, Figueiredo S, Harrois A, Bellin MF, Monnet X, Meyrignac O; COMEBAC study group. Soliman S, et al. Among authors: montani d. Eur Radiol. 2024 Feb;34(2):1037-1052. doi: 10.1007/s00330-023-10044-0. Epub 2023 Aug 12. Eur Radiol. 2024. PMID: 37572192
OBJECTIVES: Whether COVID-19 leads to long-term pulmonary sequelae or not remains unknown. The aim of this study was to assess the prevalence of persisting radiological pulmonary fibrotic lesions in patients hospitalized for COVID-19. ...CLINICAL RELEVANCE STATEMENT: Wheth …
OBJECTIVES: Whether COVID-19 leads to long-term pulmonary sequelae or not remains unknown. The aim of this study was to assess the pr …
[Post-COVID-19 syndrome].
Montani D, Savale L, Noel N, Meyrignac O, Colle R, Gasnier M, Corruble E, Beurnier A, Jutant EM, Pham T, Lecoq AL, Papon JF, Figuereido S, Harrois A, Humbert M, Monnet X; pour le Groupe d’étude Comebac. Montani D, et al. Bull Acad Natl Med. 2023 Jun;207(6):812-820. doi: 10.1016/j.banm.2023.01.029. Epub 2023 Apr 25. Bull Acad Natl Med. 2023. PMID: 37292432 Free PMC article. Review. French.
Vaccination, on the other hand, seems to reduce their incidence. The sheer number of affected patients makes long-term COVID-19 syndrome a public health challenge....
Vaccination, on the other hand, seems to reduce their incidence. The sheer number of affected patients makes long-term COVID-19 syndr …
2022 Update of indications and contraindications for lung transplantation in France.
Le Pavec J, Pison C, Hirschi S, Bunel V, Mordant P, Brugière O, Guen ML, Olland A, Coiffard B, Renaud-Picard B, Tissot A, Brioude G, Borie R, Crestani B, Deslée G, Stelianides S, Mal H, Schuller A, Falque L, Lorillon G, Tazi A, Burgel PR, Grenet D, De Miranda S, Bergeron A, Launay D, Cottin V, Nunes H, Valeyre D, Uzunhan Y, Prévot G, Sitbon O, Montani D, Savale L, Humbert M, Fadel E, Mercier O, Mornex JF, Dauriat G, Reynaud-Gaubert M. Le Pavec J, et al. Among authors: montani d. Respir Med Res. 2023 Jun;83:100981. doi: 10.1016/j.resmer.2022.100981. Epub 2022 Nov 28. Respir Med Res. 2023. PMID: 36565563
The considerable developments have been driven over the years by indefatigable work conducted at LTx centers to improve donor and recipient selection, combined with multifaceted efforts to overcome challenges raised by the surgical procedure, perioperative care, and long-term …
The considerable developments have been driven over the years by indefatigable work conducted at LTx centers to improve donor and recipient …
The evolving landscape of pulmonary arterial hypertension clinical trials.
Weatherald J, Boucly A, Peters A, Montani D, Prasad K, Psotka MA, Zannad F, Gomberg-Maitland M, McLaughlin V, Simonneau G, Humbert M; Evolving Landscape of Pulmonary Arterial Hypertension and Redesigning Pulmonary Arterial Hypertension Clinical Trials Task Force of the 18th Global CardioVascular Clinical Trialists Forum. Weatherald J, et al. Among authors: montani d. Lancet. 2022 Nov 26;400(10366):1884-1898. doi: 10.1016/S0140-6736(22)01601-4. Lancet. 2022. PMID: 36436527 Review.
Pulmonary arterial hypertension trial design has shifted from short-term submaximal exercise capacity as a primary endpoint, to larger clinical event-driven trial outcomes. ...
Pulmonary arterial hypertension trial design has shifted from short-term submaximal exercise capacity as a primary endpoint, to large …
[Updated indications and contraindications in 2022 for lung transplantation in France].
Le Pavec J, Pison C, Hirschi S, Bunel V, Mordant P, Brugière O, Le Guen M, Olland A, Coiffard B, Renaud-Picard B, Tissot A, Brioude G, Borie R, Crestani B, Deslée G, Stelianides S, Mal H, Schuller A, Falque L, Lorillon G, Tazi A, Burgel PR, Grenet D, De Miranda S, Bergeron A, Launay D, Cottin V, Nunes H, Valeyre D, Uzunhan Y, Prévot G, Sitbon O, Montani D, Savale L, Humbert M, Fadel E, Mercier O, Mornex JF, Dauriat G, Reynaud-Gaubert M. Le Pavec J, et al. Among authors: montani d. Rev Mal Respir. 2022 Dec;39(10):855-872. doi: 10.1016/j.rmr.2022.10.005. Epub 2022 Nov 10. Rev Mal Respir. 2022. PMID: 36372607 Review. French.
Major developments have been impelled over the years by painstaking efforts at LTx centers to improve donor and recipient selection, and multifaceted attempts have been made to meet the challenges raised by surgical management, perioperative care, and long-term medical com …
Major developments have been impelled over the years by painstaking efforts at LTx centers to improve donor and recipient selection, and mul …
Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension.
Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman AB, Ghofrani HA, Escribano Subias P, Feldman J, Meyer G, Montani D, Olsson KM, Manimaran S, de Oliveira Pena J, Badesch DB. Humbert M, et al. Among authors: montani d. Eur Respir J. 2023 Jan 6;61(1):2201347. doi: 10.1183/13993003.01347-2022. Print 2023 Jan. Eur Respir J. 2023. PMID: 36041750 Free PMC article. Clinical Trial.
BACKGROUND: In participants with pulmonary arterial hypertension, 24 weeks of sotatercept resulted in a significantly greater reduction from baseline in pulmonary vascular resistance than placebo. This report characterises the longer-term safety and efficacy of sotatercept …
BACKGROUND: In participants with pulmonary arterial hypertension, 24 weeks of sotatercept resulted in a significantly greater reduction from …
Pulmonary veno-occlusive disease associated with long-term occupational exposure to chemical solvents and pesticides. A case report.
Triantafyllidi H, Iordanidis D, Montani D, Samiotis E, Mademli M, Vlachos S, Mpahara A, Humbert M, Dorfmuller P, Tsagkaris I, Iliodromitis E. Triantafyllidi H, et al. Among authors: montani d. Respir Med Res. 2022 Nov;82:100943. doi: 10.1016/j.resmer.2022.100943. Epub 2022 Jul 4. Respir Med Res. 2022. PMID: 35905554 No abstract available.
60 results